Piqray from Novartis is FDA indicated to treat hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. The FDA indication requires the use of an FDA-approved test following progression on or after an endocrine-based regimen.